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Abstract
Background
Antiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been
unable to extend survival in large patient cohorts. However, a subset of patients having
angiogenesis-dependent tumors might benefit from these therapies. Currently, there are no
biomarkers allowing to discriminate responders from non-responders before the start of the
therapy.
Methods
40 patients from the randomized GENOM009 study complied the inclusion criteria (quality
of images, clinical data available). Of those, 23 patients received first line temozolomide
(TMZ) for eight weeks and then concomitant radiotherapy and TMZ. 17 patients received
BVZ+TMZ for seven weeks and then added radiotherapy to the treatment. Clinical variables
were collected, tumors segmented and several geometrical measures computed including:
Contrast enhancing (CE), necrotic, and total volumes; equivalent spherical CE width; sev-
eral geometric measures of the CE ‘rim’ geometry and a set of image texture measures.
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The significance of the results was studied using Kaplan-Meier and Cox proportional haz-
ards analysis. Correlations were assessed using Spearman correlation coefficients.
Results
Kaplan-Meier and Cox proportional hazards analysis showed that total, CE and inner vol-
ume (p = 0.019, HR = 4.258) and geometric heterogeneity of the CE areas (p = 0.011, HR =
3.931) were significant parameters identifying response to BVZ. The group of patients with
either regular CE areas (small geometric heterogeneity, median difference survival 15.88
months, p = 0.011) or those with small necrotic volume (median survival difference 14.50
months, p = 0.047) benefited substantially from BVZ.
Conclusion
Imaging biomarkers related to the irregularity of contrast enhancing areas and the necrotic
volume were able to discriminate GBM patients with a substantial survival benefit from BVZ.
A prospective study is needed to validate our results.
Introduction
Glioblastoma (GBM) is the most frequent type of malignant primary brain tumor and the
most lethal type. The standard of care includes maximal safe surgery plus concurrent treatment
with temozolomide (TMZ) and radiotherapy followed by maintenance TMZ, what leads to a
median survival of 14.6 months [1].
Since GBM is one of the most vascularized human tumors it was thought that antiangio-
genic treatment approaches might offer an alternative or complementary treatment strategy.
Specifically, bevacizumab (BVZ), a humanized monoclonal antibody, has been in the spotlight
of antiangiogenic approaches for several years [2].
Three randomized comparative phase III trials, two for newly diagnosed patients (AVA-
GLIO {ClinicalTrials.gov number NCT00943826} and RTOG08025 {ClinicalTrials.gov number
NCT00884741}) [3,4] and one for recurrent GBMs (EORTC 26101{ClinicalTrials.gov number
NCT01290939}) [5], reported negative results for the primary endpoint of overall survival (OS)
but significant positive results for the BVZ arm in terms of progression-free survival (PFS) and
overall response rate (ORR).
Nevertheless, there is a widespread, albeit statistically unsupported, perception that some
patients do benefit from BVZ and that a response to BVZ predicts longer survival [6]. In fact, a
population-based report highlighted an increase in survival among US GBM patients only
attributable to the generalized use of BVZ in the recurrent setting following FDA approval [7].
Unfortunately, there is no reliable way to preselect patients who are most likely to respond
to BVZ. Several studies have examined the possibility of selecting patients based on their
molecular profile [8, 9] or on an early detection of response by image analysis [10,11,12,13].
Preoperative Magnetic resonance imaging (MRI) is routinely used for diagnosis, treatment
planning, response evaluation and follow-up. Typical GBM appearance upon diagnosis on
MRI consists of an enhancing ring mass with central non-enhancing core of necrosis observed
mainly on contrast enhanced T1-weighted images; this is surrounded by an area of signal
hyperintensity on fluid-attenuated inversion recovery FLAIR or T2 images representing edema
that is well known to contain infiltrated tumor cells.
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The areas of signal hyperintensity, were the contrast agent is released, indicate abnormal
vessel permeability due to either the breakup of the blood-brain-barrier or the presence of
inmature tumoral vessels. Typically, those areas have enhanced perfusion and its presence
related to angiogenic processes.
There is an increasing evidence supporting that the geometrical and textural properties of
tumors can lead to novel imaging biomarkers of prognosis and response. Pérez-García et al
[14] developed a mathematical model predicting a positive correlation between the tumor rim
width as observed in the postcontrast T1-weighted MRIs and tumor’s aggressiveness. This was
later validated on a set of 117 GBM patients [15]. Other works have studied classical geometri-
cal (volumetric) measures obtained from pretreatment T1 images as prognostic “biomarkers”
[16,17]. Also, textural features in brain cancer have been widely studied to investigate their
prognostic value [18,19], discriminate tumor phenotypes [20] or automatically detection and
classification of low and high grade glioma [21,22].
The applicability of this kind of analysis to assess response to antiangiogenic treatment has
not been put forward before.
In this paper we characterized the geometry and texture of pretreatment contrast enhancing
(CE) areas in T1 weighted MRI images and correlated the resulting measures with survival ben-
efits from BVZ. Our goal was to find novel imaging biomarkers predictive of antiangiogenic
treatment efficacy in GBM patients.
Materials and Methods
Patients
The GENOM009 trial {ClinicalTrials.gov number NCT01102595} was a multicenter, prospec-
tive trial of neo-adjuvant therapy including 93 unresected patients with diagnosed GBM [23].
Patients were randomized 1:1 to either the temozolomide (TMZ) or the BVZ (TMZ+BVZ)
arm. In the TMZ arm, neoadjuvant treatment consisted of TMZ for 2 cycles and then concur-
rent treatment with radiation therapy plus TMZ. In the TMZ+BVZ arm, patients received the
same regimens but with the addition of BVZ in the neoadjuvant stage and concurrent stage. In
both arms, the concurrent stage was followed by a 28-day break in treatment and then by adju-
vant treatment with TMZ for six cycles without BVZ. The primary endpoint was investigator-
assessed response after the neoadjuvant stage (week 9) according to the Response Assessment
in Neuro-Oncology (RANO) Criteria [24]. Secondary endpoints were PFS, OS, 1-year survival
among others. Results of this trial have been recently published showing that the addition of
BVZ conferred a higher response rate (22.9% vs 6.7%; P<0.001) and greater clinical benefit
(60.4% vs 24.5%; P<0.001). These results were confirmed upon centralized blinded review.
PFS (4.8 vs 2.2 months) and OS (10.6 vs 7.7 months) were also longer in patients treated with
the combination of TMZ+BVZ, though the difference did not reach statistical significance.
The inclusion criteria for this work were: availability of all of the relevant clinical variables
(age, overall survival, etc.) and availability of high quality (no movement or other artifacts) pre-
treatment postcontrast T1-weighted MRIs. Multifocal GBMs and tumors without contrast
enhancement were excluded from the study. Overall survival was measured from time of sur-
gery to patient’s last contact or death.
High-resolution pre-surgery postcontrast T1-weighted MRIs were available for 53 patients,
of which 13 were discarded due to either no contrast enhancement, diffuse data or presence of
MRI noise. Therefore, 40 patients complied with inclusion criteria, 17 in the TMZ+BVZ arm
and 23 in the TMZ arm. Patients' characteristics are summarized in Table 1.
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Table 2 lists patients age [25], Performance Status, Barthel index [26], and macroscopic
tumor volume [15] for the different subgroups used in this study. There a high similarity
between the different groups in terms of classical prognostic variables.
The GENOM-009 trial, including centralized review of imaging was approved by the insti-
tutional review boards (IRB) of each participating hospital and subsequently countersigned by
the IRB of the Hospital Germans Trias i Pujol and approved by Spanish Agency for Medicines
and Health Products (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS).
Written informed consent was obtained from all patients before registration. (EUDRACT:
2009-010337-45).
Image analysis. The DICOM files were imported into the scientific software package
Matlab (R2015b, The MathWorks, Inc., Natick, MA, USA) and pre-processed using a semi-
automatic image segmentation procedure. Segmented tumors were manually corrected by an
image analysis expert with four years of experience with GBMMRIs.
Geometrical measures. After the segmentation, a set of geometrical 3D measures were
computed automatically [15]. First, we calculated volumetric measures on the reconstructed
tumors: the CE volume (VCE), the volume surrounded by the CE areas or inner volume (VI)
and the total postcontrast T1 tumor volume (V = VCE + VI). In most of the cases the inner vol-
ume corresponds to necrotic areas. Also the maximum tumor diameter in 3D (dmax 3D) and
some measures of the tumor surface irregularity were computed.
Table 1. Summary of patient characteristics, MRI data and volumetric parameters for the 40 patients
included in the study.
Patient characteristics
Age (median, range) 64 (36–74)
Sex 21 Male (52.50%)
19 Female (47.50%)
Survival (median, range) 10.78 months (2.30–52.33)
Treatment group 17 Temozolomide+Bevacizumab (42.50%)
23 Temozolomide (57.50%)
MRI characteristics (mean and range)
Pixel spacing (mm) 0.67 (0.43–1.04)
Slice thickness (mm) 2.54 (0.80–6.00)
Slices per patient 142 (16–301)
Relevant volumetric parameters (mean and range)
Tumor volume (V) (cm3) 28.32 (0.99–79.23)
Contrast enhancing volume (VCE) (cm
3) 19.99 (0.99–68.11)
Maximal tumor diameter (cm) 5.55 (1.48–10.57)
Spherical rim width (cm) 0.67 (0.25–2.07)
doi:10.1371/journal.pone.0161484.t001
Table 2. Comparison of classical prognostic biomarkers values between the different patient subgroups.
Genom009 Present study BVZ+ (present study) BVZ- (present study)
Number of patients 93 40 17 23
Median age (Interquartile range) [Interval] 63 (13.00)[36, 79] 64 (14.50)[36, 74] 63 (8.00)[51, 74] 64 (15.00)[36, 74]
Average Performance Status(Standard deviation)
[Interval]
1.09(0.69)[0.0, 2.0] 1.00(0.78)[0.0, 2.0] 0.82(0.81)[0.0, 2.0] 1.13(0.76)[0.0, 2.0]
Average Barthel index(Standard deviation)
[Interval]
86.89(15.26)[50.0,
100.0]
87.25(15.19)[55.0,
100.0]
90.00(15.10)[55.0,
100.0]
85.22(15.26)[55.0,
100.0]
Average Tumor volume (Standard deviation)
[Interval]
- 28.32(23.31)[1.00,
79.23]
26.24(25.21)[1.00,
79.23]
29.85(22.26)[1.16,
69.18]
doi:10.1371/journal.pone.0161484.t002
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The average size for the CE rim was called spherical rim width (δs) because it can be
obtained from a spherical approximation of the total and CE volume, using the formula
ds ¼
ﬃﬃﬃﬃﬃ
3
4p
3
r
ð
ﬃﬃﬃﬃ
V3
p
 ﬃﬃﬃﬃﬃﬃV I3p Þ  0:62ð ﬃﬃﬃﬃV3p  ﬃﬃﬃﬃﬃﬃV I3p Þ
In order to characterize the structure of the CE rim we constructed the surfaces enclosing
the CE areas (inner and outer). For every point in these surfaces the minimal distance to the
other surface was computed, providing a set of distances, that was used to construct histograms
of rim sizes. This histogram was characterized by many measures (median, mean, positions of
the quartiles, etc). Of them, the most relevant found was the geometric heterogeneity of the CE
rim width (GH). This is defined as the difference between the values of the quartile 4 and 3 of
the distribution of the CE rim widths divided by the quartile 4, i.e.
GH ¼
ðd4  d3Þ
d4
The geometric heterogeneity uses the difference between the values of quartiles 4 and 3, i.e.
the size of the region of the most asymmetric distances of the tumor, divided by the longest rim
width in the tumor. This is a normalized measure of the tumor’s asymmetry that gets values in
the range [0, 1].
Fig 1 shows characteristic slices of two different tumors and the corresponding values of GH
obtained for each tumor. The first case (Fig 1A) corresponds to a heterogeneous tumor with a
broad range of distances between the inner zones and the outer part of the CE rim. The second
case (Fig 1C) corresponds to a geometrically more regular tumor. Fig 1B and 1D show their
respective associated histograms of distances, from where the geometrical heterogeneity is
computed. The presence of both large and small distances leads to more dispersed histograms,
thus larger GH (Fig 1B). More regular tumors lead to lower dispersion of widths and smaller
values of GH (Fig 1D).
Heterogeneity measures. A set of 16 3D heterogeneity textural measures was also com-
puted automatically using Matlab software. The measures considered are based in the classical
co-occurrence [27] and run-length matrices [28]. Co-occurrence matrix is a classical tool for
heterogeneity computation providing information on local heterogeneity by describing the
arrangements of pairs of elements (voxels) within the tumor. The run-length matrix character-
izes groups of voxels within the tumor to provide information on regional heterogeneity.
Table 3 lists the textural features considered.
Statistical methods. To identify geometric parameters associated with prognosis we used
Kaplan–Meier plots and log-rank analysis. A 2-tailed significance level (p-value) of p<0.05 was
applied. We tried to find measures separating patient populations in two groups with signifi-
cant differences in terms of survival. To do so we: (i) computed the p-values for the full range
of thresholds of each variable considered in the study, (ii) accepted only thresholds that sepa-
rated the populations on reasonably-sized subgroups, and (iii) looked minimum p-values
located in low p-value regions of the parameter space (in order to discard purely statistical fluc-
tuations). For each population splitting, we computed the hazard ratio (HR) as an indicator of
risk by using a single-variable Cox proportional hazards regression analysis.
In order to identify measures with similar information, we computed the correlations
between the significant variables of the previous analysis. Because of the normality analysis,
Spearman's correlation coefficient was considered to study the relation between independent
quantitative variables. Correlation coefficient values<0.1 were taking as indicators of no
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correlation between the variables while values>0.7 were taken as indicators of strong correla-
tion between the variables.
Results
We segmented and geometrically analyzed brain imaging datasets belonging to the 40 patients
included in our study (Table 1). By means of Kaplan-Meier analysis, we first compared survival
of patients receiving TMZ+BVZ with those only receiving TMZ. While there seems to be a bet-
ter survival for patients in the TMZ+BVZ arm, the result was statistically non-significant
(p = 0.107) for the subset of patients from the Genom009 trial included in this study, what is in
line with the clinical trial results.
Next, we studied the geometrical and heterogeneity measures described in the methods sec-
tion using Kaplan-Meier curves and Cox proportional hazard analysis. Patients were split into
subgroups as described in the methods section. Table 4 summarizes the results for the different
population splits using the mean, the median and the optimal thresholds used for each signifi-
cant variable. Thresholds were computed for the BVZ group and then the statistical analysis
was performed for both arms.
The best thresholds for V, VI, VCE and GH were found to be 5 cm
3 (p = 0.019), 2.5 cm3
(p = 0.019), 3.5 cm3 (p = 0.019) and 0.605 (p = 0.011) respectively (see Table 4). The increases
in the median survival times for the favorable subgroups were of 19.72 months (V<5 cm3,
Fig 1. Visual examples of two tumors with different geometric heterogeneities. The first case corresponds to
a rim-heterogeneous tumor (Fig 1A and 1B), having large geometric heterogeneity. The second case is a
geometrically regular tumor (Fig 1C and 1D), with smaller geometric heterogeneity.
doi:10.1371/journal.pone.0161484.g001
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VI<2.5 cm
3 and VCE<3.5 cm
3) and 19.40 months (GH<0.605). None of the studied image het-
erogeneity features reached statistical significance.
Fig 2C, 2E, 2G and 2I show Kaplan-Meier survival curves for the significant variables of our
study. The three different volumetric measures considered (V, VI and VCE) led to the same pop-
ulation splitting and thus the same Kaplan-Meier curves (shown in Fig 2C, 2E and 2G). This is
due to the limited number of patients in the study and high correlation between the volumetric
Table 3. Definition of the heterogeneity measures computed in this study.
Type of measure Name Formula
Co-occurrence matrix Entropy [27]

XN
i¼1
XN
j¼1
CMði; jÞ  ln½CMði; jÞ
Co-occurrence matrix Homogeneity [27] XN
i¼1
XN
j¼1
CMði; jÞ
1þ ði  jÞ2
Co-occurrence matrix Contrast [27] XN
i¼1
XN
j¼1
CMði; jÞ  ði  jÞ2
Co-occurrence matrix Dissimilarity [27] XN
i¼1
XN
j¼1
CMði; jÞ  ji  jj
Co-occurrence matrix Uniformity [27] XN
i¼1
XN
j¼1
½CMði; jÞ2
Run-length matrix Long Run Emphasis (LRE) [28]
1
nr
XN
i¼1
XM
j¼1
RLMði; jÞ  j2
Run-length matrix Short Run Emphasis (SRE) [28]
1
nr
XN
i¼1
XM
j¼1
RLMði; jÞ
j2
Run-length matrix Low Gray-level Run Emphasis (LGRE) [28]
1
nr
XN
i¼1
XM
j¼1
RLMði; jÞ
i2
Run-length matrix High Gray-level Run Emphasis (HGRE) [28]
1
nr
XN
i¼1
XM
j¼1
RLMði; jÞ  i2
Run-length matrix Short Run Low Gray-level Emphasis (SRLRE) [28]
1
nr
XN
i¼1
XM
j¼1
RLMði; jÞ
i2  j2
Run-length matrix Short Run High Gray-level Emphasis (SRHGE) [28]
1
nr
XN
i¼1
XM
j¼1
RLMði; jÞ  i2
j2
Run-length matrix Long Run Low Gray-level Emphasis (LRLGE) [28]
1
nr
XN
i¼1
XM
j¼1
RLMði; jÞ  j2
i2
Run-length matrix Long Run High Gray-level Emphasis (LRHGE) [28]
1
nr
XN
i¼1
XM
j¼1
RLMði; jÞ  i2  j2
Run-length matrix Gray-Level Non-Uniformity (GLNU) [28]
1
nr
XN
i¼1
XM
j¼1
RLMði; jÞ
2
Run-length matrix Run-Length Non-Uniformity (RLNU) [28]
1
nr
XM
j¼1
XN
i¼1
RLMði; jÞ
2
Run-length matrix Run Percentage (RPC) [28] nrXN
i¼1
XM
j¼1
RLMði; jÞ  j
For CMmeasures CM(i,j) stands for the co-occurrence matrix, N is the number of classes of gray-levels taken (32 in this study). For RLMmeasures RLM(i,j)
is the run-length matrix, nr is the number of runs, N is the number of classes of gray-levels and M is the size in voxels of the largest region found.
doi:10.1371/journal.pone.0161484.t003
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features. We also show the best threshold for the age (Fig 2A) although this variable was only
marginally significant in our study. In order to discard purely statistical fluctuations, we stud-
ied the same computed thresholds on the TMZ only arm. Fig 2B, 2D, 2F, 2H and 2J show the
corresponding Kaplan-Meier survival curves.
The next step in our analysis was to compare patients having the same geometrical charac-
teristics and study whether BVZ provides any significant benefits. To do so, for each variable
found to be significant in the previous analysis, we separated the initial 40 patients between
those being above or below the selected best threshold. Then, we used Kaplan-Meier analysis to
compare patients in both trial arms. Fig 3 summarizes our results.
The outstanding feature of this analysis was the contrast enhancing rim geometric heteroge-
neity GH (Fig 3I and 3J). Patients having a small GH had a significant strong benefit from BVZ
(p = 0.011, Fig 3I) with a median survival difference of 15.88 months. On the other hand,
patients with large GH (p = 0.930. Fig 3J) did not present any benefit from BVZ.
The necrotic volume VI also showed significant results in terms of survival (Fig 3C and 3D).
Patients having a small VI strongly benefited from BVZ (p = 0.047, Fig 3C) with a median sur-
vival of 15.52 months. On the other hand, patients with large VI (p = 0.328. Fig 3D) did not
present any benefit from BVZ.
As next step, we computed the Spearman’s correlation coefficient and the associated p
between all significant variables (Table 5). It is relevant to point out that the volumetric vari-
ables (VCE, VI, V) were mutually correlated and weakly (but significantly in most cases) corre-
lated with the geometric heterogeneity GH.
Table 6 shows the computed values of the geometric heterogeneity and the necrotic volumes
for all patients included in this study, together with their overall survival and O(6)-Methylgua-
nine-DNA-methyltransferase (MGMT) status. Patients in the first part of the table (those
Table 4. Summary of univariate Cox and Kaplan-Meier analysis for the more representative variables included in the study. Significant results are
boldfaced.
17 patients (BVZ) 23 patients (No BVZ)
Variables HR, (CI-95%) p-value HR, (CI-95%) p-value
Age (years)
Age (< = 65.00 vs >65.00) (years) 2.721 (0.879, 8.425) 0.072 2.331 (0.864, 6.285) 0.084
Mean: Age (< = 63.00 vs >63.00) (years) 2.485 (0.846, 7.299) 0.088 1.341 (0.573, 3.138) 0.496
Median: Age (< = 63.00 vs >63.00) (years) 2.485 (0.846, 7.299) 0.088 1.341 (0.573, 3.138) 0.496
VI (cm3) (Necrotic volume)
VI (< = 2.50 vs >2.50) (cm
3) 4.258 (1.160. 15.635) 0.019 2.140 (0.855, 5.361) 0.096
Mean: VI (< = 7.32 vs >7.32) (cm
3) 1.099 (0.389, 3.106) 0.858 1.843 (0.757, 4.488) 0.171
Median: VI (< = 4.49 vs >4.49) (cm
3) 1.549 (0.552, 4.348) 0.402 1.843 (0.757, 4.488) 0.171
V (cm3) (Total volume)
V (< = 5.00 vs >5.00) (cm3) 4.258 (1.160. 15.635) 0.019 1.502 (0.432, 5.228) 0.519
Mean: V (< = 26.24 vs >26.24) (cm3) 1.927 (0.635, 5.850) 0.239 1.453 (0.615, 3.435) 0.391
Median: V (< = 21.28 vs >21.28)(cm3) 2.676 (0.845, 8.471) 0.083 1.824 (0.749, 4.443) 0.178
VCE (cm3) (CE volume)
VCE (< = 3.50 vs >3.50) (cm
3) 4.258 (1.160. 15.635) 0.019 1.502 (0.432, 5.228) 0.519
Mean: VCE (< = 18.91 vs >18.91) (cm
3) 2.676 (0.845, 8.471) 0.083 1.288 (0.545, 3.047) 0.562
Median: VCE (< = 14.40 vs >14.01) (cm
3) 3.445 (1.008, 11.770) 0.038 1.824 (0.749, 4.443) 0.178
GH (Geometric heterogeneity)
GH (< = 0.605 vs >0.605) 3.931 (1.289, 11.985) 0.011 1.070 (0.441, 2.596) 0.881
Mean:GH (< = 0.608 vs >0.608) 3.050 (1.050. 8.856) 0.032 1.070 (0.441, 2.596) 0.881
Median:GH (< = 0.623 vs >0.623) 3.050 (1.050. 8.856) 0.032 1.268 (0.362, 4.438) 0.709
doi:10.1371/journal.pone.0161484.t004
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taking only TMZ) having large overall survival could be mostly identified by the presence of
the MGMTmethilation, due to its relation with the response to temozolomide. On the other
hand, patients in the BVZ group (second part of Table 6) with long survivals were strongly
identified by GH.
Discussion
Personalized medicine is becoming one of the major research topics in medicine and specifi-
cally in oncology [29]. Researchers have discovered genes that harbor variations contributing
to human cancers, identified genetic variability in patients’ responses to different treatments,
and begun to target the causes of some tumors. This requires the use of diagnostic tests able
to predict patients’ responses to the therapies. Imaging biomarkers in different types of can-
cers [30,31] and specifically in GBM [32,33] are receiving a lot of attention recently as an
alternative or complement to the more ‘standard’ tests based on genetics or other molecular
mechanisms.
Experimental data indicate that the most important angiogenic signaling pathway in glio-
mas involves the vascular endothelial growth factor (VEGF) and its receptor VEGFR-2. BVZ is
a human recombinant monoclonal antibody specific for the VEGF ligand that is being used to
treat recurrent GBM in spite of the scarcity of direct evidence of increased survival with such
treatment compared to other existing alternatives [34].
Imaging biomarkers have been found in GBM to determine prognosis [15,19,32,33,35] and
to assess the response to antiangiogenic therapies [36]. Specifically, to distinguish progression
from pseudoprogression or to provide early indications of treatment response in recurrent
GBMs [12,13,31].
Our goal in this study was to test if a set of geometrical [15] and heterogeneity [19,27,28]
features obtained from pretreatment postcontrast T1 weighted MRIs, some of them found pre-
viously to have a prognostic value, were predictors of response to antiangiogenic therapies.
When the group of patients receiving BVZ was considered, and for several geometrical vari-
ables, we found thresholds splitting this group into subgroups with significant differences in
survival. When the same threshold was found to split the population of patients receiving only
TMZ there were no significant differences between both subgroups. This means that the
thresholds found are not just indicating a better prognosis group for the whole GBM patient
population but instead reflecting a different response to the therapy in the different groups.
The analysis developed points out to two geometric parameters: the necrotic volume VI and
the geometric heterogeneity GH as potential predictors of BVZ effectivity. Due to the limited
number of patients available VI was only marginally significant what points out the need for
further prospective studies.
It is remarkable that patients with small values of the geometric heterogeneity of the con-
trast enhancing rim, in many cases being the same ones as those with small necrotic volumes,
were the ones having more benefits from therapy. These tumors (small GH and VI) display uni-
form contrast enhancement and small necrotic cores with rounded shapes. It has been demon-
strated using mathematical models that that harsh tumor microenvironment conditions exert a
dramatic selective force on the tumor, which grows as an invasive mass with fingering margins,
dominated by a few clones with aggressive traits [37]. In the specific case of GBM those
Fig 2. Kaplan-Meier curves for the each significant geometrical variable (plus age, that was marginally
significant) using the thresholds of Table 4: (a,b) age, (c,d) VI, (e,f) V, (g,h) VCE and (i,j)GH. The median
differences, p-values and number of patients per group are indicated in each subplot. Panels (a, c, e, g and i)
correspond to patients in the BVZ+TMZ arm while panels (b, d, f, h and j) correspond to the TMZ arm.
doi:10.1371/journal.pone.0161484.g002
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Fig 3. Kaplan-Meier curves comparing survival of subgroups of patients below or above the optimal
thresholds shown in Table 4: (a,b) age, (c,d) VI, (e,f) V, (g,h) VCE and (i,j)GH. The median differences, p-
values and number of patients in each subgroup are indicated.
doi:10.1371/journal.pone.0161484.g003
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conditions arise after hypoxic events, that lead to the generation of necrotic areas and the accel-
eration of tumor growth and the development of more aggressive and infiltrative phenotypes
[38,39]. Thus, in line with recent mathematical models [14], we think that these tumors are
probably in the early steps of their natural history and are still more dependent on angiogenesis
for their development.
In contrast, mild microenvironment conditions allow clones with similar aggressive traits to
coexist with less aggressive phenotypes in a heterogeneous tumor mass with smooth, noninva-
sive margins [37]. Thus, the genetic make-up of a cancer cell may realize its invasive potential
through a clonal evolution process driven by definable microenvironmental selective forces.
The presence of necrosis and/or large values of the geometric heterogeneity would be a macro-
scopic reflection of these microscopic processes.
Table 5. Spearman correlation coefficients between every pair of significant variables in our study.
Boldfaced numbers indicate significant correlations (p<0.05).
VI V VCE GH
VI 1 0.790 0.670 0.522
V 1 0.963 0.322
VCE 1 0.253
GH 1
doi:10.1371/journal.pone.0161484.t005
Table 6. Overall survival,GH, VI and MGMT status (when available) for all of the patients included in the study. Within each group (BVZ+ or BVZ-)
patients are ordered by survival. Grey cells indicate patients in the favourable groups: either smallGH (dark grey) or unmethilated MGMT (light grey).
BVZ- BVZ+
Patient OS VI GH MGMT Patient OS VI GH MGMT
1 70 14.182 0.611 1 24 72 2.979 0.752 1
2 71 0.070 0.444 - 25 121 4.135 0.623 0
3 71 0.439 0.292 0 26 128 3.866 0.635 1
4 82 39.114 0.719 0 27 131 12.598 0.607 0
5 86 8.699 0.609 0 28 213 6.401 0.792 1
6 102 3.640 0.562 0 29 294 6.875 0.633 1
7 126 1.422 0.395 0 30 311 30.054 0.721 -
8 132 8.243 0.572 0 31 336 19.244 0.698 0
9 144 2.384 0.467 0 32 395 0.220 0.588 0
10 176 10.236 0.589 0 33 416 4.486 0.544 1
11 227 16.513 0.621 - 34 511 11.819 0.662 -
12 245 2.349 0.646 - 35 683 0.011 0.368 -
13 320 14.882 0.505 - 36 803 11.677 0.531 1
14 375 30.470 0.623 0 37 894 1.884 0.601 1
15 416 3.695 0.453 1 38 932 7.473 0.723 -
16 422 0.872 0.539 1 39 1363 0.093 0.346 1
17 453 0.054 0.235 0 40 1592 0.682 0.509 1
18 494 26.232 0.589 1
19 533 1.527 0.412 1
20 584 20.928 0.581 -
21 629 0.825 0.610 -
22 909 0.353 0.725 -
23 1205 1.546 0.402 0
doi:10.1371/journal.pone.0161484.t006
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Indeed, the mesenchimal GBM subtype is known to generate large necrotic areas, have
higher infiltration and could be less dependent on angiogenesis than tumors with the prolifer-
ative molecular subtype [40]. For our patients genomic data was not available but it would be
very interesting to correlate these macroscopic features with genomic data on the light of the
GBMmolecular classification.
As mentioned before, the main limitation of our study is the small number of patients, due
to the restrictive inclusion criteria imposed. Specifically, high resolution images (3D T1) are
necessary to obtain reliable values for the geometrical parameters in general and very specifi-
cally to compute GH. This is why Genom009 was a good candidate trial to include its patients
in our study, since neoadjuvant treatment (BEV and TMZ or TMZ) was administered as first-
line treatment before radiotherapy, thus, removing the effects of radiotherapy over the blood
brain barrier that produce secondary changes in contrast enhancement and difficult the
response assessment as the study was performed over basal, pretreatment MRI. A prospective
study design with high resolution images, in agreement with current recommendations [41], is
necessary to confirm the potential clinical applicability of the imaging biomarkers defined
here.
Conclusions
Two geometrical features obtained from high resolution postcontrast and pretreatment MRI
T1-weighted images were predictive of benefit from BVZ: the geometric heterogeneity of the
contrast-enhancing rim and the necrotic volume. Our results suggest that this drug may have a
substantial potential benefit on a subset of patients with tumors having regular geometries or
very small necrotic volumes. The measurement, study and validation of these characteristics
may be key to plan treatment and predict response and evolution of GBM patients. A prospec-
tive study is necessary to corroborate our results.
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